Ignite Creation Date:
2025-12-24 @ 5:47 PM
Ignite Modification Date:
2025-12-25 @ 3:14 PM
Study NCT ID:
NCT01014468
Status:
UNKNOWN
Last Update Posted:
2011-11-22
First Post:
2009-11-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
Sponsor:
Instituto de Olhos de Goiania
Organization:
Study Overview
Official Title:
Comparative Study - Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
Status:
UNKNOWN
Status Verified Date:
2011-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AxL-2009
Brief Summary:
To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.
Detailed Description:
We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.25 mg bevacizumab or 0.5 mg ranibizumab and had a follow-up of at least 3 months. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: